Trial Profile
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Alpha 1-antitrypsin deficiency; Emphysema
- Focus Registrational; Therapeutic Use
- Acronyms SPARTA
- Sponsors Grifols
- 06 Mar 2024 Planned End Date changed from 1 Aug 2026 to 1 Jan 2027.
- 24 Jan 2024 Planned End Date changed from 1 Jul 2026 to 1 Aug 2026.
- 24 Jan 2024 Planned primary completion date changed from 1 Jul 2026 to 1 Aug 2026.